Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 4, 2014, Pages 2438-2440

  Bizerra, Fernando César ^a   Jimenez Ortigosa, Cristina ^c   Souza, Ana Carolina R ^a   Breda, Giovanni Luis ^b   Queiroz Telles, Flávio ^b   Perlin, David S ^c   Colombo, Arnaldo L ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^c PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; CEFEPIME; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ECHINOCANDIN; FLUCONAZOLE; INTERNAL TRANSCRIBED SPACER; LEVOFLOXACIN; MICAFUNGIN; PYRROLE DERIVATIVE; VINCRISTINE;

ADULT; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BACTERIAL GENE; BLOOD CULTURE; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANDIDA GLABRATA; CANDIDEMIA; CASE REPORT; CONTROLLED STUDY; DNA SEQUENCE; DRUG DOSE INCREASE; FKS2 GENE; FUNGUS ISOLATION; FUNGUS MUTATION; HOSPITAL ADMISSION; HUMAN; INFECTION PREVENTION; LOW DRUG DOSE; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NEUTROPENIA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; AZOLES; CANDIDA GLABRATA; CANDIDEMIA; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FUNGAL PROTEINS; HUMANS; LIPOPEPTIDES; MALE; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION;

EID: 84896930228     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02189-13     Document Type: Article

References (23)

1. Colombo AL, Garnica M, Aranha Camargo LF, Da Cunha CA, Bandeira AC, Borghi D, Campos T, Senna AL, Valias Didier ME, Dias VC, Nucci M. 2013. Candida glabrata: an emerging pathogen in Brazilian tertiary care hospitals. Med. Mycol. 51:38-44. http://dx.doi.org/10.3109/13693786.2012.698024.
2. Moretti ML, Trabasso P, Lyra L, Fagnani R, Resende MR, de Oliveira Cardoso LG, Schreiber AZ. 2013. Is the incidence of candidemia caused by Candida glabrata increasing in Brazil? Five-year surveillance of Candida bloodstream infection in a university reference hospital in southeast Brazil. Med. Mycol. 51:225-230. http://dx.doi.org/10.3109/13693786.2012.708107.
3. Nucci M, Queiroz-Telles F, Alvarado-Matute T, Tiraboschi IN, Cortes J, Zurita J, Guzman-Blanco M, Santolaya ME, Thompson L, Sifuentes-Osornio J, Echevarria JI, Colombo AL, Latin American Invasive Mycosis Network. 2013. Epidemiology of candidemia in Latin America: a laboratory-based survey. PLoS One 8:e59373. http://dx.doi.org/10.1371/journal.pone.0059373.
4. Pfaller MA, Diekema DJ, International Fungal Surveillance Participant Group. 2004. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin. Microbiol. Infect. 10(Suppl 1):11-23. http://dx.doi.org/10.1111/ j.1470-9465.2004.t01-1-00844.x. (Pubitemid 38386593)
5. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, Infectious Diseases Society of America. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535. http://dx.doi.org/10.1086/596757.
6. Ullmann AJ, Cornely OA, Donnelly JP, Akova M, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bille J, Calandra T, Castagnola E, Garbino J, Groll AH, Herbrecht R, Hope WW, Jensen HE, Kullberg BJ, Lass-Flörl C, Lortholary O, Meersseman W, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Cuenca-Estrella M, ESCMID Fungal Infection Study Group. 2012. ESCMID guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. Clin. Microbiol. Infect. 18(Suppl 7):1-8. http://dx.doi.org/10.1111/1469-0691.12037.
7. Colombo AL, Guimarães T, Aranha Camargo LF, Richtmann R, Queiroz-Telles F, Salles MJC, da Cunha CA, Yasuda MAS, Moretti ML, Nucci M, Consenso Brasileiro de Infecções por Candida Group. 2012. Brazilian guidelines for the management of candidiasis: a joint meeting report of three medical societies: Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia, Sociedade Brasileira de Medicina Tropical. Braz J. Infect. Dis. 17:283-312. http://dx.doi.org/10.1016/j.bjid.2013.02.001.
8. Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer AS, Perlin DS, Pfaller MA. 2013. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin. Infect. Dis. 57:1724-1732. http://dx.doi.org/10.1093/cid/cit136.
9. Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. 2012. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J. Clin. Microbiol. 50:1199-1203. http://dx.doi.org/10.1128/JCM.06112-11.
10. Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, Alexander BD. 2010. Breakthrough invasive candidiasis in patients on micafungin. J. Clin. Microbiol. 48:2373-2380. http://dx.doi.org/10.1128/JCM.02390-09.
11. Garcia-Effron G, Kontoyiannis DP, Lewis RE, Perlin DS. 2008. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob. Agents Chemother. 52:4181-4183. http://dx.doi.org/10.1128/AAC.00802-08.
12. Souza ACR, Ferreira RC, Gonçalves SS, Quindós G, Eraso E, Bizerra FC, Briones MRS, Colombo AL. 2012. Accurate identification of Candida parapsilosis (sensu lato) using mitochondrial DNA and real-time PCR. J. Clin. Microbiol. 50:2310-2314. http://dx.doi.org/10.1128/JCM.00303-12.
13. White TJ, Bruns TD, Lee SB, Taylor JW. 1990. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics, p 315-322. In Innis MA, Gelfand DH, Sninsky JJ, White TJ (ed), PCR protocols: a guide to methods and applications. Academic Press, Inc., San Diego, CA.
14. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard - 3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
15. Clinical and Laboratory Standards Institute. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts; fourth informational supplement. CLSI document M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA.
16. Castanheira M, Woosley LN, Diekema DJ, Messer SA, Jones RN, Pfaller MA. 2010. Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. Antimicrob. Agents Chemother. 54:2655-2659. http://dx.doi.org/10.1128/AAC.01711-09.
17. Garcia-Effron G, Lee S, Park S, Cleary JD, Perlin DS. 2009. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother. 53:3690-3699. http://dx.doi.org/10.1128/AAC.00443-09.
18. Garcia-Effron G, Park S, Perlin DS. 2009. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob. Agents Chemother. 53:112-122. http://dx.doi.org/10.1128/AAC.01162-08.
19. Park S, Kelly R, Kahn JN, Robles J, Hsu MJ, Register E, Li W, Vyas V, Fan H, Abruzzo G, Flattery A, Gill C, Chrebet G, Parent SA, Kurtz M, Teppler H, Douglas CM, Perlin DS. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49:3264-3273. http://dx.doi.org/10. 1128/AAC.49.8.3264-3273.2005. (Pubitemid 41060570)
20. Zimbeck AJ, Iqbal N, Ahlquist AM, Farley MM, Harrison LH, Chiller T, Lockhart SR. 2010. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob. Agents Chemother. 54:5042-5047. http://dx.doi.org/10.1128/AAC.00836-10.
21. Garcia-Effron G, Chua DJ, Tomada JR, Dipersio J, Perlin DS, Ghannoum M, Bonilla H. 2010. Novel FKS mutations associated with echinocandin resistance in Candida species. Antimicrob. Agents Chemother. 54:2225-2227. http://dx.doi.org/10.1128/AAC.00998-09.
22. Costa-de-Oliveira S, Marcos Miranda I, Silva RM, Pinto e Silva A, Rocha R, Amorim A, Gonçalves Rodrigues A, Pina-Vaz C. 2011. FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy. Antimicrob. Agents Chemother. 55:1312-1314. http://dx.doi.org/10.1128/AAC.00589-10.
23. Lewis JS, Jr, Wiederhold NP, Wickes BL, Patterson TF, Jorgensen JH. 2013. Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure. Antimicrob. Agents Chemother. 57:4559-4561. http://dx.doi.org/10.1128/AAC.01144-13.